Resveratrol/SRT501. Sirtuin SIRT1 activator treatment of type 2 diabetes

Drugs of the Future

Volumn 34, Issue 4, 2009, Pages 291-295

  Elliott, P J ^a   Walpole, S M ^a   Morelli, L ^a   Lambert, P D ^a   Lunsmann, W ^a   Westphal, C H ^a   Lavu, S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; RESVERATROL; SIRTUIN 1; SRT 501; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETIC PATIENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 76649084868     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.04.1360696     Document Type: Review

References (36)

1. Lin, SJ., Defossez, P.A., Guarente, L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000, 289(5487): 2126-8.
2. Anderson, R.M., Latorre-Esteves, M., Neves, A.R. et al. Yeast life-span extension by calorie restriction is independent of NAD fluctuation. Science 2003, 302(5653): 2124-6.
3. Cohen, H.Y., Miller, C., Bitterman, K.J. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305(5682): 390-2.
4. Bordone, L., Guarente, L. Calorie restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol 2005, 6(4): 298-305.
5. Sinclair, D.A., Guarente, L. Unlocking the secrets of longevity genes. Sci Am 2006, 294(3): 48-51, 54-7.
6. Pearson, K.J., Baur, J.A., Lewis, K.N. et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008, 8(2): 157-68.
7. Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl. 1): S12-54.
8. Heilbronn, L.K., de Jonge, L., Frisard, M.I. et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. JAMA 2006, 295(13): 1539-48.
9. Sigal, R.J., Kenny, G.P., Wasserman, D.H., Castaneda-Sceppa, C. Physical activity/exercise and type 2 diabetes. Diabetes Care 2004, 27(10): 2518-39.
10. Takaoka, M.J. Faculty of Science, Hokkaido Imperial University 1940, 13.
11. Harikumar, K.B., Aggarwal, B.B. Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7(8): 1020-35.
12. Howitz, K.T., Bitterman, K.J., Cohen, H.Y. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425(6954): 191-6.
13. Miyazaki, R., Ichiki, T., Hashimoto, T., Inanaga, K., Imayama, I., Sadoshima, J., Sunagawa, K. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle sells. Arterioscler Thromb Vasc Biol 2008, 28(7): 1263-9.
14. Parker, J.A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., Neri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005, 37(4): 349-50.
15. Picard, F., Kurtev, M., Chung, N. et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429(6993): 771-6.
16. Yeung, F., Hoberg, J.E., Ramsey, C.S., Keller, M.D., Jones, D.R., Frye, R.A., Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23(12): 2369-80.
17. Lagouge, M., Argmann, C., Gerhart-Hines, Z. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127(6): 1109-22.
18. Harper, C.E., Patel, B.B., Wang, J., Arabshahi, A., Eltoum, I.A., Lamartiniere, C.A. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007, 28(9): 1946-53.
19. Lavu, S., Boss, O., Elliott, P.J., Lambert, P.D. Sirtuins - Novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008, 7(10): 841-53.
20. Csiszar, A., Labinskyy, N., Podlutsky, A. et al. Vosoprotective effects of resveratrol and SIRT1: Attenuation of cigarette smoke-induced oxidative stress and pro-inflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008, 294(6): H2721-35.
21. Baur, J.A., Pearson, K.J., Price, N.L. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117): 337-42.
22. Silan, C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull 2008, 31(5): 897-902.
23. Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., Zhai, Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007, 6(4): 307-19.
24. Sharma, S., Anjaneyulu, M., Kulkarni, S.K., Chopra, K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006, 76(2): 69-75.
25. Boocock, D.J., Faust, G.E., Patel, K.R. et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007, 16(6): 1246-52.
26. Boocock, D.J., Patel, K.R., Faust, G.E. et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 848(2): 182-7.
27. Burkon, A., Somoza, V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O- conjugated diglucuronides - Two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008, 52(5): 549-57.
28. Goldberg, D.M., Yan, J., Soleas, G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003, 36(1): 79-87.
29. Lekakis, J., Rallidis, L.S., Andreadou, I. et al. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005, 12(6): 596-600.
30. Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E. Jr., Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32(12): 1377-82.
31. Meng, X., Maliakal, P., Lu, H., Lee, M.J., Yang, C.S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004, 52(4): 935-42.
32. Vitaglione, P., Sforza, S., Galaverna, G. et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005, 49(5): 495-504.
33. Zeng, D., Mi, Q., Sun, H., Wang, H. A convenient synthesis of 14C-labelled resveratrol. J Label Compd Radiopharm 2004, 47(3): 167-74.
34. Elliott, P.J., Jirousek, M. Sirtuins: Novel targets for metabolic disease. Curr Opin Investig Drugs 2008, 9(4): 371-8.
35. Juan, M.E., Vinardell, M.P., Planas, J.M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002, 132(2): 257-60.
36. Crowell, J.A., Korytko, P.J., Morrissey, R.L., Booth, T.D., Levine, B.S. Resveratrol-associated renal toxicity. Toxicol Sci 2004, 82(2): 614-9.